Tennor Therap-b (06872.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 8.79B

MomentumView details →

1D Return

−3.34%

YTD Return

—

RSI (14)

35.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 8.79B

RSI (14)

35.2

MomentumView details →

1D Return

−3.34%

YTD Return

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−99.60%

ROA (TTM)

−67.50%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−4.96%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.19x

Current Ratio

5.02x

Quick Ratio

5.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Dano Pharmaceutical-B (06872.HK) reported interim results for the six months ended June 2026, with net loss narrowing to RMB 64.245 million from RMB 78.17 million in the same period last year, and no dividend declared.9d ago

Similar companies

ST诺泰688076.SH CStone Pharmaceuticals02616.HK 中源协和600645.SH Crinetics Pharmaceuticals, Inc.CRNX TG Therapeutics, Inc.TGTX ImmunityBio, Inc.IBRX Find similar companies →

Latest newsMore news →

Dano Pharmaceutical-B (06872.HK) reported interim results for the six months ended June 2026, with net loss narrowing to RMB 64.245 million from RMB 78.17 million in the same period last year, and no dividend declared.9d ago